ICON plc (ICLR) : ICON plc (ICLR) had a healthy money flow of $1.1 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $3.96 million, whereas, investors only sold shares worth $2.87 million on downticks. The stock closed the day with an up-down ratio of 1.38.The money flow in the block trades to the tune of $0.92 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0.92 million worth of transactions were on upticks. ICON plc (ICLR) stock slid $0.07 intraday and traded at 76.78, a change of -0.09% over previous days close. However, for the week, the company shares are 1.98% compared to previous weeks close.
The company Insiders own 44% of ICON plc shares according to the proxy statements. Institutional Investors own 96.29% of ICON plc shares.
ICON plc (NASDAQ:ICLR): The stock opened at $76.93 and touched an intraday high of $77.2 on Friday. During the day, the stock corrected to an intraday low of $76.45, however, the bulls stepped in and pushed the price higher to close in the green at $77.14 with a gain of 0.38% for the day. The total traded volume for the day was 347,477. The stock had closed at $76.85 in the previous trading session.
ICON plc (ICLR) : Traders are bullish on ICON plc (ICLR) as it has outperformed the S&P 500 by a wide margin of 1.05% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.94%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.46% in the last 1 week, and is up 0.92% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO), providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. ICONs services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. ICON also conducts various laboratory tests on the patients blood, urine and other bodily fluids at appropriate intervals during the trial. The Companys information systems offerings include ICONIK, Firecrest, iDOC, iLearn, ADDPLAN, AptivAdvantage and AptivInsite. ICON, through its subsidiaries, also provides payer-validated market access solutions, and clinical trial consulting and regulatory support.